Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Restructuring Costs (2023)

Rein Therapeutics (RNTX) has disclosed Restructuring Costs for 1 consecutive years, with -$12000.0 as the latest value for Q4 2023.

  • Quarterly Restructuring Costs changed N/A to -$12000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$12000.0 through Sep 2024, changed N/A year-over-year, with the annual reading at $928000.0 for FY2023, N/A changed from the prior year.
  • Restructuring Costs for Q4 2023 was -$12000.0 at Rein Therapeutics, down from $6000.0 in the prior quarter.
  • The five-year high for Restructuring Costs was $1.0 million in Q1 2023, with the low at -$88000.0 in Q2 2023.